Clinical Psychopharmacology

Neuropharmacology I Parkinson s Disease and Movement Disorders

Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Dr. David Standaert Standaert 1 Neuropharmacology I Parkinson s Disease and Movement Disorders What

Anti-Parkinsonism Drugs

Anti-Parkinsonism Drugs Pharma Team 429 Fahad Alrumaih Ibrahim Alshiddi Sultan Alsalem Ismail Raslan Suhail Asiri Parkinsonism - Could be: primary [idiopathic] or secondary [viral infection or drug induced

Dementia & Movement Disorders

Dementia & Movement Disorders A/Prof Michael Davis Geriatrician ACT Health & GSAHS ANU Medical School Eastern Dementia Network Aged and Dementia Care Symposium Bateman s Bay, 22 October 2010 Types of Dementia

GLOSSARY OF TERMS. This glossary explains the terms and words often used in association with Parkinson s.

Antagonist This glossary explains the terms and words often used in association with Parkinson s. Medications which have a negative effect on particular cells in the body. In Parkinson s dopamine antagonists

Chapter 28. Drug Treatment of Parkinson s Disease

Chapter 28 Drug Treatment of Parkinson s Disease 1. Introduction Parkinsonism Tremors hands and head develop involuntary movements when at rest; pin rolling sign (finger and thumb) Muscle rigidity arthritis

Management of Parkinson s Disease in Primary Care

Management of Parkinson s Disease in Primary Care Dr June Tan National University Hospital System (NUHS) Division of Neurology Senior Consultant Topics: Diagnosing PD Choice of medication in the de novo

Motor Fluctuations in Parkinson s

Motor Fluctuations in Parkinson s What are motor fluctuations? Motor fluctuations are associated with longterm use of levodopa (trade names Sinemet or Madopar, Co-careldopa or Co-beneldopa), and usually

CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE

MANAGEMENT CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE Parkinson s Disease is classically determined by the triad or rest tremor (usually starting in one arm) with bradykinesia (slowing of

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Section 4.9: Drugs Used in Parkinsonism and related Disorders Co-Beneldopa 12.5/50, 25/100 and 50/200 (Madopar) Capsules Co-Beneldopa 12.5/50 and 25/100 Dispersible

PARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB

PARKINSON S DISEASE AND PARKINSONISM Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB OUTLINE Covering:- Why this is an important area of Medical and Psychiatric care The variety

Parkinson s Disease - A Junior Doctor s Survival Guide

Parkinson s Disease - A Junior Doctor s Survival Guide Professor Richard Walker Consultant Geriatrician Hon. Professor of Ageing & Interna

Understanding Parkinson s Disease

Understanding Parkinson s Disease Irene Oh, MD Neurologist, Movement Disorders Specialist The Neurology Center of Southern California, Encinitas & Escondido Introduction PD was first described in 1817

Drug-induced movement

FEATURE Recognizing and managing drug-induced movement disorders Reprint from DUE Quarterly, July 2003 RICHARD CAMICIOLI, MD, Department of Medicine, University of Alberta, Edmonton, AB NOREEN VANDERBURGH,

Pharmacology of the Central Nervous System (CNS) Dr. Sabry Attia. November 2006

Pharmacology of the Central Nervous System (CNS) Dr. Sabry Attia November 2006 Neurodegenerative disease Neurodegenerative disease is a condition which affects brain function. They are result from deterioration

How To Treat Aphasic Depression

Antipsychotic Use in Patients with Parkinson s Disease 단국의대 정신과 이석범 Difficulties in Parkinson's disease Motor symptoms Neuropsychiatric syndromes Severe Disability Cognitive impairment 2 Neuropsychiatric

Acute management of Parkinson s

Acute management of Parkinson s Fife Parkinson s Service 2013 1 Contents 1. Introduction 2. On admission to hospital 3. If Patient has compromised swallow or is nil by mouth 4. Conversion charts if patient

Movement Disorders and Extrapyramidal System. Doç.. Dr. Sibel Ertan

Movement Disorders and Extrapyramidal System Doç.. Dr. Sibel Ertan İ.Ü.. CTF. Nöroloji N ABD. Motor System I. neuron (corticospinal pathway) Extrapyramidal system (basal ganglia) Cerebellum Loops for praxis

Parkinson s Disease and Dementia. Dr N Samaniego Consultant Physician and Geriatrician

Parkinson s Disease and Dementia Dr N Samaniego Consultant Physician and Geriatrician Case 68 year old female. Off legs for a few months, O/E no neurological deficit. -Slowing down -Needs help with dressing,

Multiple System Atrophy

Multiple System Atrophy U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health Multiple System Atrophy What is multiple system atrophy? Multiple system atrophy

Parkinson's s disease - a

Parkinson's Disease Parkinson's s disease - a progressive disorder of the nervous system that affects movement. The most common perception of Parkinson s is the patient having tremors. Hands shaking, inability

Motor dysfunction 2: Spinal cord injury and subcortical motor disorders ANATOMY REVIEW: Basal Ganglia

Motor dysfunction 2: Spinal cord injury and subcortical motor disorders ANATOMY REVIEW: Basal Ganglia A group of subcortical nuclei caudate, putamen, globus pallidus Caudate & Putamen = Neostriatum caudate

Movement Disorders: Diagnosis i and Treatment. Movement Disorders: Classification

Movement Disorders: Diagnosis i and Treatment Lawrence Elmer, MD, PhD Professor Dept. of Neurology University of Toledo College of Medicine Movement Disorders: Review Movement Disorders: Classification

Movement Disorder Emergencies. Anne E. A. Constantino, MD Attending Neurologist Holy Cross Hospital Silver Spring, MD June 28, 2014

Movement Disorder Emergencies Anne E. A. Constantino, MD Attending Neurologist Holy Cross Hospital Silver Spring, MD June 28, 2014 Objectives Provide a working definition of movement disorder emergencies

Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013

Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses 26 April 2013 1 Parkinson s Disease & Multiple Sclerosis Dr Nick Niven Jenkins 2 Movement Human

Mr James Garrard University of Leicester May 2014

Parkinson s disease exemplifies the art and science of geriatric medicine. Introduction First described by Dr. James Parkinson in the classic essay The Shaking Palsy in 1817 (1), Parkinson s disease is

Parkinson s disease. 14 June 2012

Parkinson s disease 14 June 2012 Cardinal sign of parkinsonism As least 2/4 for diagnosis Resting tremor Bradykinesia Rigidity Postural instability Classification Idiopathic Parkinson disease Secondary

The majority of parkinsonism (approx. 80%) is due to idiopathic PD other causes include drug therapy (Table 1),toxins and trauma.

THE TREATMENT OF PARKINSON S DISEASE SUMMARY Levodopa (L-dopa) administered in conjunction with a dopa decarboxylase inhibitor (DDCI) remains the mainstay of therapy for Parkinson s disease. New drugs

III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases

III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases III./3.1.2.1. Multiple System Atrophy (MSA) MSA is a sporadic, adult onset degenerative neurological

Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders

Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders Karen Frei, Erik Ch. Wolters Abstract: The twentieth World Congress on Parkinson s Disease and Related Disorders was held

Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of

Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects

Basal Ganglia. Motor systems

409 systems Basal Ganglia You have just read about the different motorrelated cortical areas. Premotor areas are involved in planning, while MI is involved in execution. What you don t know is that the

9/20/2010. Disclaimer. Movement Disorders in Psychiatry. Overview of Key Points: Learning Objectives:

Movement Disorders in Psychiatry Badari Birur,MD PGY4 Psychiatry Resident ETSU James H. Quillen College of Medicine Disclaimer NEITHER THE PUBLISHER NOR THE AUTHORS ASSUME ANY LIABILITY FOR ANY INJURY

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making

Cerebellum and Basal Ganglia

Cerebellum and Basal Ganglia 1 Contents Cerebellum and Basal Ganglia... 1 Introduction... 3 A brief review of cerebellar anatomy... 4 Basic Circuit... 4 Parallel and climbing fiber input has a very different

Pharmacological Management of Parkinson s Disease Robert Iansek

GERIATRIC THERAPEUTICS Editors: Associate Professor Michael Woodward, Director, Aged and Residential Care Services, Dr Margaret Bird, Consultant Geriatrician, Mr Rohan Elliott, Clinical Pharmacist, Austin

Parkinson s Disease and Tremors

Parkinson s Disease and Tremors Current Strategies Leah Karliner, MD, MAS Division of General Internal Medicine Disclosures I have no conflicts of interest Parkinsonism neurological syndrome: Bradykinesia:

Personal Health Record

Personal Health Record Contents Section 1: Personal details (pages 4 6) Within this section you can note all information about you, next of kin, important health information and general medical history.

Chapter 20 USE OF DRUGS FOR NEUROLOGICAL DISORDER

Chapter 20 USE OF DRUGS FOR NEUROLOGICAL DISORDER Sapiah S. 1, Mohd. Sufian A. 1, Norsima Nazifah S. 2, Nurul Faezah M.Y. 2, Khutrun Nada Z. 1, Md. Hanip M.R. 1 1. Kuala Lumpur Hospital, Kuala Lumpur,

Journal Club. Parkinsonismo iatrogeno

PROGETTO UNIVA 2013 Journal Club Parkinsonismo iatrogeno Pietro Gareri, MD, PhD Geriatra ASP Catanzaro Lamezia Terme 3 Luglio 2013 Drug-induced parkinsonism (DIP) was recognized in the early 1950s as a

Unmet Needs for Parkinson s Disease Therapeutics

Unmet Needs for Parkinson s Disease Therapeutics Coalition Against Major Diseases & FDA Workshop October 20, 2014 Caroline M Tanner MD, PhD Director, Parkinson's Disease Research Education and Clinical

Chapter 372. Parkinson's Disease and Other Movement Disorders

Harrison's Principles of Internal Medicine, 18e > Chapter 372. Parkinson's Disease and Other Movement Disorders C. Warren Olanow; Anthony H.V. Schapira Parkinson's Disease and Related Disorders Parkinson's

ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD

ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD What is Parkinson s Disease? Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually,

drug treatments for parkinson s

drug treatments for parkinson s While there is no cure yet for Parkinson s, there are many different drugs that can help manage the symptoms. This booklet is for people with Parkinson s and their families.

Part 1 of a 6-Part Series

Release Date: April 1, 2003. Termination Date: April 1, 2004. Estimated time to complete this 6-part newsletter series: 3.0 hours. For additional updates, go to www.projectsinknowledge.com Awake and Involved:

Management in the pre-hospital setting

Management in the pre-hospital setting Inflammation of the joints Two main types: Osteoarthritis - cartilage loss from wear and tear Rheumatoid arthritis - autoimmune disorder Affects all age groups,

Parkinson's Disease Glossary

Parkinson's Disease Glossary A guide to the scientific language of Parkinson s disease for the non-scientist Acetylcholine: One of the chemical neurotransmitters in the brain and other areas of the central

COMPASS Therapeutic Notes on Management of Parkinson s Disease

COMPASS Therapeutic Notes on Management of Parkinson s Disease In this issue Page Introduction 1 Drug Treatment in 3 early PD Motor 9 complications Depression in PD 11 Dementia in PD 13 Psychosis in PD

Understanding Antipsychotic Medications

Understanding Antipsychotic Medications NARSAD RESEARCH National Alliance for Research on Schizophrenia and Depression 60 Cutter Mill Road, Suite 404 Great Neck, NY 11021 516-829-0091 1-800-829-8289 516-487-6930

What s New in Multiple Sclerosis and Parkinson Disease?

What s New in Multiple Sclerosis and Parkinson Disease? Eric S. Farbman, MD University of Nevada School of Medicine Division of Neurology Director of Movement Disorders Center Disclosures Member of Parkinson

Parkinson Disease Levodopa-Induced Dyskinesia. Christopher Kenney, MD Novartis Pharmaceuticals

Parkinson Disease Levodopa-Induced Dyskinesia Christopher Kenney, MD Novartis Pharmaceuticals Disclosures Dr. Kenney is a full-time employee of Novartis Pharmaceuticals Corporation The opinions expressed

Emergency management of patients with Parkinson s

Emergency management of patients with Parkinson s Missing doses of Parkinson s medication increases care needs and can cause serious complications, including rare but potentially fatal neuroleptic-like

Public Assessment Report. Dopamine agonists: pathological gambling and increased libido TABLE OF CONTENTS

Public Assessment Report Dopamine agonists: pathological gambling and increased libido TABLE OF CONTENTS Summary 2 Introduction 4 Data considered 5 Published literature 9 Discussion 14 Conclusions and

Chad Christine, MD UCSF

Parkinsonism: Clinical Features and Treatments Parkinson's disease is a condition whose main features are slowed movement, tremor, and gait or balance problems. More than1 million people in the United

drug treatments for parkinson s

drug treatments for parkinson s 1 While there is no cure yet for Parkinson s, there are many different drugs that can help manage the symptoms. This booklet is for people with Parkinson s and their families.

EBM Parkinson s Diseases

Parkinson s Diseases Version 1 Final Page 1 Document control Version history Version Date Comments 1e (draft) 30 March 2007 Comments from customer incorporated 1d (draft) 22 January 2007 Formatting 1c

NEUROIMAGING in Parkinsonian Syndromes

NEUROIMAGING in Parkinsonian Syndromes (Focus on Structural Techniques: CT and MRI) Dr. Roberto Cilia Parkinson Institute, ICP, Milan, Italy OUTLINE Primary Parkinsonism Idiopathic Parkinson s Disease

PARKINSONISM. akinetic-rigid syndrome

PARKINSONISM PARKINSONISM akinetic-rigid syndrome PARKINSONISM Symptoms of Parkinson s disease: akinesia, bradykinesia, rigidity, postural instability, gait impairment, tremor A common, age-related syndrome

What You Need to Know About Xenazine

Note to Healthcare Professionals: Please provide this guide to your patient or your patient s caregiver. What You Need to Know About Xenazine (tetrabenazine) Patient/Caregiver Counseling Guide This guide

MEDICATIONS AND PARKINSON'S DISEASE Cathi A.Thomas R.N., M.S.

MEDICATIONS AND PARKINSON'S DISEASE Cathi A.Thomas R.N., M.S. Medications to relieve or decrease symptoms of Parkinson s disease are an important and necessary part of care. For some people this may be

Diagnosing Parkinson s disease (PD) in

MedicineToday 2015; 16(1): 12-18 PEER REVIEWED FEATURE 2 CPD POINTS The clinical challenge of early Parkinson s disease SIMON J.G. LEWIS MB BCh, BSc, MRCP, FRACP, MD Early Parkinson s disease may be challenging

Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature

Evidence Report/Technology Assessment Number 57 Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature Prepared for: Agency for Healthcare Research and Quality U.S. Department

1/25/2015. Idiopathic restless legs syndrome: clinical definition, pathophysiology and treatment. Five essential criteria (all must be met)

Idiopathic restless legs syndrome: clinical definition, pathophysiology and treatment Joan Santamaria, MD Neurology service, Multidisciplinary Sleep Disorders Unit Hospital Clínic de Barcelona University

SUMMARY OF RECOMMENDATIONS

SUMMARY OF RECOMMENDATIONS FOR THE LONG- TERM TREATMENT OF RLS/WED from AN IRLSSG TASK FORCE Members of the Task Force Diego Garcia- Borreguero, MD, Madrid, Spain* Richard Allen, PhD, Baltimore, MD, USA*

Circuit Disorders of the Basal Ganglia: Parkinson s Disease Pathophysiology and Surgical Treatments

Circuit Disorders of the Basal Ganglia: Parkinson s Disease Pathophysiology and Surgical Treatments Mahlon R. DeLong M.D. W. P. Timmie Professor of Neurology Emory University School of Medicine The Basal

Introduction to Psychology, 7th Edition, Rod Plotnik Module 3: Brain s Building Blocks. Module 3. Brain s Building Blocks

Module 3 Brain s Building Blocks Structure of the Brain Genes chains of chemicals that are arranged like rungs on a twisting ladder there are about 100,000 genes that contain chemical instructions that

cme: The Current Treatment of Parkinson's Disease

cme: The Current Treatment of Parkinson's Disease Lars Wojtecki, Martin Südmeyer, Alfons Schnitzler SUMMARY Introduction: Parkinson s disease is a neurodegenerative disease characterized by akinesia, rigidity,

Illinois Department of Revenue Regulations TITLE 86: REVENUE CHAPTER I: DEPARTMENT OF REVENUE

Illinois Department of Revenue Regulations Title 86 Part 530 Section 530.110 Covered Prescription Drugs TITLE 86: REVENUE CHAPTER I: DEPARTMENT OF REVENUE PART 530 SENIOR CITIZENS AND DISABLED PERSONS

The Neuron and the Synapse. The Neuron. Parts of the Neuron. Functions of the neuron:

The Neuron and the Synapse The Neuron Functions of the neuron: Transmit information from one point in the body to another. Process the information in various ways (that is, compute). The neuron has a specialized

PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O.

PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O. Parkinson's disease is a common neurologic disorder. It affects people of all ages and ethnic backgrounds and

Levels of evidence and grades of recommendation

MOH Clinical Practice Guidelines 6/2007 Levels of evidence and grades of recommendation Levels of Evidence Level Type of Evidence 1 ++ High quality meta analyses, systematic reviews of RCTs, or RCTs with

Parkinsonism What makes it different?

What is Parkinsonism? Parkinsonism What makes it different? Praween Lolekha, MD. MSc. Neurology division, Department of Internal Medicine Thammasat University A motor syndrome with the following cardinal

Nursing Care of Patients with Movement Disorders. Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014

Nursing Care of Patients with Movement Disorders Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014 Types of Movement Disorders Parkinson s disease Huntington s disease Dystonia Tremors

Rörelserubbningar och Parkinson, hur svårt kan det vara. En översikt och problematisering av en folksjukdom Örjan Skogar, MD,PhD

Rörelserubbningar och Parkinson, hur svårt kan det vara En översikt och problematisering av en folksjukdom Örjan Skogar, MD,PhD Man räknar med att 11-19 personer /100 000 invånare insjuknar i Parkinson

SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.

SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P. Problems with sleep are common in Parkinson s disease. They can sometimes interfere with quality of life. It is helpful to

Disordered sleep at night has long been

Neurology 59 Excessive daytime sleepiness in PD Excessive Daytime Sleepiness (EDS) in Parkinson s disease (PD) is an important issue that warrants serious attention because it can have adverse effects

PARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.

PARKINSON S DISEASE INTRODUCTION Parkinson s disease is a disorder of the brain and the nervous system. It is one of the more common neurological diseases in people over the age of 60, and it is more common

Parkinson s Disease Medications

Parkinson s Disease Medications By David Houghton, MD, MPH, Howard Hurtig, MD, and Sharon Metz, RN, MPH, with guest author Melanie Brandabur, MD Table of Contents Chapter 1 Introduction to Parkinson s

Parkinson s Disease. Challenges, Progress and Hope

Parkinson s Disease Challenges, Progress and Hope Parkinson s Disease: Challenges, Progress and Hope Course #226 5 Contact Hours Author: Ellen Steinbart, RN, MA Course Material valid through 09/2016 Copyright

Management of Parkinson s disease and co-existent health problems is a long journey, requiring a multidisciplinary team approach.

Diagnosis and management of Parkinson s Disease Key points 1. 2. 3. 4. 5. 6. The diagnosis of Parkinson s disease is still based on careful history taking and clinical examination, despite ongoing advances

NEURON AND NEURAL TRAMSMISSION: ANATOMY OF A NEURON. created by Dr. Joanne Hsu

NEURON AND NEURAL TRAMSMISSION: ANATOMY OF A NEURON NEURON AND NEURAL TRAMSMISSION: MICROSCOPIC VIEW OF NEURONS A photograph taken through a light microscope (500x) of neurons in the spinal cord. NEURON

Parkinson s Disease: General Information

Parkinson s Disease: General Information Does PD come in stages? If so, how many stages? Hubert Fernandez, MD: Staging provides an artificial classification of a patient's illness severity but, in reality,

Understanding tardive dyskinesia

Understanding tardive dyskinesia 1 Contents What is tardive dyskinesia? 3 What does TD look like? 3 What might affect the risk of me getting TD? 4 Will TD disappear if I stop my medication? 5 What else

Contemporary Psychiatric-Mental Health Nursing. Assessing the Effectiveness of Medications. Administering Medications

Contemporary Psychiatric-Mental Health Nursing Chapter 32 Psychopharmacologic Nursing Interventions Assessing the Effectiveness of Medications Include how well the medications are helping the client to

A GUIDE FOR THE NEW PATIENT. supported by the Neurological Foundation

PARKINSON S A GUIDE FOR THE NEW PATIENT supported by the Neurological Foundation INTRODUCTION 1 Contents 1. Introduction 2. Parkinson s 3. The main symptoms of Parkinson s 6. What causes Parkinson s? 7.

PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS

PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS De Anna Looper, RN CHPN Corporate Clinical Consultant / Legal Nurse Consultant Carrefour Associates L.L.C. PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS

PRODUCT MONOGRAPH. Pr PROLOPA. levodopa and benserazide combination. Capsules 50-12.5, 100-25, 200-50. Pharmaceutical standard: professed

PRODUCT MONOGRAPH Pr PROLOPA levodopa and benserazide combination Capsules 50-12.5, 100-25, 200-50 Pharmaceutical standard: professed Antiparkinson Agent Hoffmann-La Roche Limited Date of Preparation:

Management of hand tremor in Primary care setting. Specialist in Family Medicine

Management of hand tremor in Primary care setting Dr. Ko Wai Kit, Welchie Specialist in Family Medicine Types of hand tremor Causes of hand tremor How to approach a hand tremor patient Management of

2015 RN.ORG, S.A., RN.ORG, LLC

Parkinson s Disease WWW.RN.ORG Reviewed September, 2015, Expires September, 2017 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2015 RN.ORG, S.A., RN.ORG,

Benzodiazepines: A Model for Central Nervous System (CNS) Depressants

Benzodiazepines: A Model for Central Nervous System (CNS) Depressants Objectives Summarize the basic mechanism by which benzodiazepines work in the brain. Describe two strategies for reducing and/or eliminating

Emergency Room Treatment of Psychosis

OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different

Movement disorders and gait disturbances. Kovács Norbert PTE ÁOK Neurológiai Klinika Pécs

Movement disorders and gait disturbances Kovács Norbert PTE ÁOK Neurológiai Klinika Pécs 1 MD pathophysiology Genetic mutation or environmental injury of basal ganglia functioning Pallidum, thalamus, subthalamic

Treatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:

Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through

Parkinson s disease is a progressive. Parkinson s Disease: Diagnosis and Treatment

: Diagnosis and Treatment SHOBHA S. RAO, M.D., LAURA A. HOFMANN, M.D., and AMER SHAKIL, M.D., University of Texas Southwestern Medical School at Dallas Family Medicine Residency Program, Dallas, Texas

CAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological

Obsessive Compulsive Disorder: a pharmacological treatment approach

Obsessive Compulsive Disorder: a pharmacological treatment approach Professor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics University of Melbourne Royal Children s Hospital

If you have been taking a Parkinson s drug that contains levodopa,

Symptoms and lifestyle Wearing off and involuntary movements (dyskinesia) If you have been taking a Parkinson s drug that contains levodopa, for example co-beneldopa or co-careldopa, for some time, you

Symptomatic treatment of Parkinson s disease: The role of transdermal iontophoretic delivery of dopamine agonists

Symptomatic treatment of Parkinson s disease: The role of transdermal iontophoretic delivery of dopamine agonists CHAPTER 1 1 Introduction Parkinson s disease (Pd) is an age-related neurodegenerative disorder.

PARKINSON S DISEASE MULTIPLE DOMAINS

PhD PROGRAM IN NEUROPHARMACOLOGY UNIVERSITY OF CATANIA SUMMER SCHOOL OF NEUROSCIENCE (5) Quinta scuola estiva di Neuroscienze (5) July 7-13, 2007 PARKINSON S DISEASE MULTIPLE DOMAINS Catania Parco degli

Parkinson s disease (PD) is a progressive neurodegenerative

n reports n Advanced Strategies for Treatment of Parkinson s Disease: The Role of Early Treatment Michael W. Jann, PharmD Parkinson s disease (PD) is a progressive neurodegenerative disease associated

Common causes of dementia

Common causes of dementia Alzheimer s disease vascular (multi-infarct etc.) dementia dementia of Parkinsonism Huntington s disease Pick s disease Creutzfeldt-Jacob disease etc. DEGENERATIVE DEMENTIA Pick